CordenPharma, GE form oligonucleotide services pact | July 17, 2017 Issue - Vol. 95 Issue 29 | Chemical & Engineering News
Volume 95 Issue 29 | p. 17 | Concentrates
Issue Date: July 17, 2017

CordenPharma, GE form oligonucleotide services pact

Department: Business
Keywords: nucleic acids, oligonucleotides, RNA, CordenPharma, GE

CordenPharma International and GE Healthcare’s Dharmacon division are joining to provide what they call an end-to-end service for oligonucleotide-based drug discovery. The GE unit offers custom synthesis of complex oligos to support research. CordenPharma provides larger-scale oligos manufacturing, a service it launched last year after investing in a Boulder, Colo., plant it acquired from Roche in 2011. CordenPharma currently supports early-stage clinical development and expects to begin commercial-scale manufacturing by the end of the year.

 
Chemical & Engineering News
ISSN 0009-2347
Copyright © American Chemical Society

Leave A Comment

*Required to comment